Related Experiment Videos
[High intensity focused ultrasound alone for malignant solid tumors]
Wenzhi Chen1, Zhibiao Wang, Feng Wu
1Clinicul Center for Tumor Therapy, Second Hospital and Institute of Ultrasonic Engineering in Medicine, Chongqing University of Medical Sciences, Chongqing 400010, China.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|January 8, 2003
Summary
High intensity focused ultrasound (HIFU) is a safe and effective treatment for malignant solid tumors. This therapy demonstrated significant tumor shrinkage and long-term survival rates in patients who did not respond to traditional treatments.
Area of Science:
- Oncology
- Medical Physics
- Interventional Radiology
Background:
- Malignant solid tumors present significant treatment challenges, especially in patients refractory to chemotherapy or unwilling to undergo surgery.
- Exploring novel, non-invasive therapeutic modalities is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the clinical efficacy and safety profile of high intensity focused ultrasound (HIFU) as a standalone treatment for malignant solid tumors.
- To assess tumor response, survival rates, and adverse events associated with HIFU therapy.
Main Methods:
- A cohort of 30 patients with malignant solid tumors, who were either refractory to chemotherapy or refused surgery, received HIFU treatment.
- Efficacy and side effects were monitored using vital signs, organ function tests, various imaging modalities (DSA, CT, MRI, SPECT), and large core needle biopsies.
Main Results:
- HIFU therapy maintained stable vital signs and normal organ function (heart, lung, kidney, liver) with no arterial damage observed.
- After a median follow-up of 23.1 months, 87% of patients survived, with 10 achieving complete tumor regression and 13 showing >50% shrinkage.
- While 10% experienced local recurrence, two were successfully retreated with HIFU. Peripheral nerve and skin injuries were reported but mostly resolved.
Conclusions:
- High intensity focused ultrasound (HIFU) monotherapy demonstrates significant efficacy in achieving tumor regression and improving survival in patients with malignant solid tumors.
- The treatment is well-tolerated, with a favorable safety profile and manageable side effects, supporting its role as a viable therapeutic option.